IL8 and serum soluble TRAIL levels following anti-VEGF monoclonal antibody treatment in patients with metastatic colon cancer

Clinical Laboratory

Volumn 58, Issue 5-6, 2012, Pages 501-505

  Kargi, Aysegul ^a   Yalcin, Arzu Didem ^b   Erin, Nuray ^c   Savas, Burhan ^c   Polat, H Hüseyin ^d   Gorczynski, Reginald M ^e  

^a Denizli Education and Research Hospital   (Turkey)

^b Antalya Education and Research Hospital   (Turkey)

^c AKDENIZ UNIVERSITY   (Turkey)

^d CUMHURIYET UNIVERSITY   (Turkey)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Anti VEGF monoclonal antibody; BevacizumAb; IL8; sTRAIL

Indexed keywords

BEVACIZUMAB; INTERLEUKIN 8; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; COLON CANCER; COLON METASTASIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLONIC NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-8; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863684007     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Valentini V, Coco C, Gambacorta MA, Barba MC, Meldolesi E. Evidence and research perspectives for surgeons in the European Rectal Cancer Consensus Conference (EURECACC2). Acta Chir Iugosl 2010;57(3):9-16.
2. Palmer G, Holm T. Survival in locally advanced rectal cancer can be improved. Optimal management with centralized investigation and treatment. Lakartidningen 2010 Sep 1-7;107(35):2014-7. Review.
3. Jass JR, Whitehall VL, Young J, et al. Emerging concepts in colorectal neoplasia. Gastroenterology 2002;123:862-76. (Pubitemid 34977092)
4. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6. (Pubitemid 23131373)
5. Nugent KP, Farmer KC, Spigelman AD,et al. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618-9. (Pubitemid 24007679)
6. Winde G, Schmid KW, Brandt B, et al. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Dis Colon Rectum 1997;40:1156-8.
7. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52. (Pubitemid 30419089)
8. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999;11:255-60. (Pubitemid 29164042)
9. Rijcken FE, Hollema H, van der Sluis T, Boersma-van Ek W, Kleibeuker JH. Sulindac increases epithelial cell proliferative activity in the proximal colon of HNPCC patients. Eur J Gastroenterol Hepatol 2005;17:A56-7.
10. Reed JC. Apoptosis-targeted therapies of cancer. Cancer Cell 2003;3:17-22.
11. Puthillath A, Patel A, Fakih MG. Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. Onco Targets Ther 2009 Feb 18;2:1-15.
12. Shi J, Zheng D, Liu Y, et al. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005 Mar 1;65(5):1687-92. Erratum in: Cancer Res 2005 May 1;65(9):3966. (Pubitemid 40478593)
13. Sanlioglu AD, Dirice E, Elpek O, et al. High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients. Pancreas 2009 Mar;38(2):154-60.
14. Yalçin AD, Bisgin A, Kargi A, Gorczynski Reginald M. Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to Omalizumab treatment. Med Sci Monit 2012;18(3):PI 11 15.
15. Yalçin AD, Gorczynski RM, Parlak GE, et al. Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment. Clin. Lab. 2012; 58(1-2):89-96.
16. Ding W, Cai T, Zhu H, et al. Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo. Cancer Lett 2010 Jul 28;293(2):158-66. Epub 2010 Feb 6.
17. Ren B, Song K, Parangi S, et al. A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res 2009 May 1;69(9):3856-65. Epub 2009 Apr 14.
18. Plastaras JP, Kozak KR. A one, two punch for liver cancer: antiangiogenesis with a death receptor agonist. Cancer Biol Ther 2009 Mar;8(5):463-4. Epub 2009 Mar 23.
19. Cantarella G, Risuglia N, Dell'eva R, et al. TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. Br J Cancer 2006;94(10):1428-35. (Pubitemid 43772277)
20. Trillet-Lenoir V, et al. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. Br J Radiol 2002.
21. Bişgin A, Kargi A, Yalcin AD, Aydin C, Şanlioǧlu S, Savas B. Increased sTRAIL levels were correlated with patient survival in BevacizumAb treated metastatic colon cancer patients. BMC Cancer 2011. doi: 1040.5847.35548055.
22. Nadal C, Maurel J, Gallego R, et al. FAS/FAS ligand ratio: a marker of oxaliplatinbased intrinsic and acquired resistance in advanced colorectal cancer. Clin Cancer Res 2005;11:4770-4. (Pubitemid 41557197)
23. van Geelen CM, Westra JL, de Vries EG, et al.Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol 2006;24:4998-5004. (Pubitemid 46631402)
24. Grand V, Bibeau F, Kramar A, et al.Prognostic significance of TRAiL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas. Eur J Cancer 2008;44:2312-8.
25. Yildiz R, Benekli M, Buyukberber S, et al.The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer. J Cancer Res Clin Oncol 2010 Oct;136(10):1471-6.
26. Ning Y, Manegold PC, Hong YK, et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer. 2011 May 1;128(9):2038-49. doi: 10.1002/ijc.25562.
27. Li A, Varney ML, Singh RK. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin Cancer Res 2001 Oct;7(10):3298-304. (Pubitemid 32963857)
28. Ishiko T, Sakamoto T, Yamashita SI, et al. Carcinoma cells express IL-8 and IL-8 receptor: their inhibition attenuates the growth of carcinoma cells. Int J Oncol 1995;6.119-22.
29. Kitadai Y, Haruma K, Sumii K, et al. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol 1998;152:93-100. (Pubitemid 28028050)
30. Yang SK, Eckmann L, Panja A, Kagnoff MF. Differential and regulated expression of C-X-C, C-C, and C-chemokines by human colon epithelial cells. Gastroenterology 1997;113:1214-23. (Pubitemid 27418975)